How GLP-1s Sustain Calorie Reduction for Over a Year

Semaglutide helps adults with overweight or obesity consistently consume 24% to 30% fewer calories and achieve an average weight loss of 15.1% over 60 weeks, according to data from a recent clinical trial examining appetite control and caloric intake. Researchers tracked 120 participants receiving either a weekly 2.4-milligram dose of the medication or a placebo alongside lifestyle counseling, finding that the treatment supports sustained long-term reductions in energy consumption despite shifting subjective hunger scores over time.

Clinical Trial Findings on Calorie Reduction and Weight Loss

The 60-week trial enrolled 120 adults with overweight or obesity. Participants received either a once-weekly 2.4-milligram dose of semaglutide or a placebo, along with regular lifestyle counseling focused on healthy eating and physical activity. At the beginning of the study and again at weeks 20, 40, and 60, participants ate standardized meals and were instructed to eat until they felt comfortably full, while researchers measured the number of calories they consumed.

Compared with those given a placebo, participants taking semaglutide consistently consumed 24% to 30% fewer calories at each follow-up assessment through week 60. This sustained reduction in calorie intake was accompanied by greater weight loss. Participants taking semaglutide lost an average of 15.1% of their initial body weight after 60 weeks, compared with 3.4% among those taking a placebo.

How Semaglutide Impacts Hunger and Food Noise

The study also examined participants’ feelings of hunger, fullness, and food preoccupation, commonly referred to as food noise. The researchers found that during the first 20 weeks, people using semaglutide reported less hunger, fewer food-related thoughts, and greater appetite control.

However, by weeks 40 and 60, the differences between those using semaglutide and the placebo group on these measures were no longer statistically significant. Despite this shift in subjective reporting, participants taking semaglutide continued to consume significantly fewer calories than those taking a placebo throughout the entire duration of the study.

“In many cases, the benefits of the medication can persist over time, although some patients may become slightly less sensitive to its effects as their bodies adjust,” said Mir Ali, MD, bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, who was not involved in the study.

Biological Mechanisms and Expert Perspectives on Long-Term Use

GLP-1 medications help control appetite by mimicking a natural gut hormone and slowing stomach emptying, which helps patients feel full longer while reducing cravings. Jonathan Jennings, MD, a board-certified internist with Medical Offices of Manhattan who also was not involved in the study, explained that obesity involves an excessive amount of internal organ fat that reduces the body’s responsiveness to insulin, thereby stimulating appetite.

“Semaglutide decreases the amount of insulin in the body, which also decreases the appetite,” Jennings said.

Medical professionals stress the importance of viewing these treatments as part of a comprehensive strategy. “I always emphasize that the most successful outcomes happen when patients use the medication as a tool and not a stand-alone solution. Long-term results are typically driven by a combination of the medication’s effects and meaningful, sustainable changes in diet and lifestyle,” Ali noted.

Jennings added that strategic planning with a nutritionist and a healthcare professional represents the most effective way to make necessary modifications and reduce the risk of rebound weight gain after discontinuing the medication. “Overall, these findings highlight the value of continued treatment for many patients. For individuals who tolerate the medication well, staying on it longer term can play an important role in maintaining weight loss and supporting ongoing metabolic health,” Ali concluded.

Frequently Asked Questions

How much weight did participants lose on semaglutide in the trial?

Participants taking semaglutide lost an average of 15.1% of their initial body weight after 60 weeks, compared with 3.4% for the placebo group, according to study results.

Does semaglutide stop reducing appetite over time?

While subjective reports of hunger and food noise showed no statistically significant difference between groups by weeks 40 and 60, participants on semaglutide continued to consume 24% to 30% fewer calories than the placebo group through week 60.

What is the recommended approach for long-term weight management with GLP-1 medications?

Experts recommend using semaglutide as a long-term medical tool combined with sustainable dietary changes, physical activity, and professional guidance from healthcare providers and nutritionists.